Drugs in Dev.
Genetic Disease
Phase IV
Canada 
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Recombinant Coagulation Factor Ix
Therapeutic Area : Genetic Disease
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Medexus reached the 50% enrollment target in its Phase 4 clinical trial investigating IXINITY® as a prophylactic treatment for pediatric patients under 12 years of age with hemophilia B.
Product Name : Ixinity
Product Type : Protein
Upfront Cash : Inapplicable
November 16, 2020
Lead Product(s) : Recombinant Coagulation Factor Ix
Therapeutic Area : Genetic Disease
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
